Ustekinumab (Stelara, Janssen Biotech) appears to be effective in the treatment of patients with severe Crohn’s disease, researchers have found.
While ustekinumab, a human monoclonal antibody, has been shown to have long-term effectiveness and durability in patients with moderate to severe Crohn’s, the new study is among the first to show that the drug is effective for patients with disease of the pouch and chronic antibiotic-dependent pouchitis (CADP), said Kimberly Weaver, MD, a